AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$TMCI

Treace John T. purchased $247K of TMCI

Treace John T. (Chief Executive Officer) purchased 55,944 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $4.41 ($4.34–$4.44, $0.25M total) across 3 trades over 2026-08-20 to 2026-08-24.

Original reporting
SEC EDGAR · Treace John T.
Published Aug 24, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TMCI
Bullish
medium confidence
Mentioned
$TMCI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMCIBullishLow
01

Why it matters

The insider purchase may be interpreted as confidence in the company's prospects, but the amount is modest.

02

Market read

Minor insider buying; limited immediate trading impact.

03

What to watch

Potential upcoming clinical or regulatory events not disclosed.

Relevance 5/10Novelty 5/10Timing: today

Background

Form 4 filing reveals insider activity for Treace Medical Concepts, Inc.

Company-level read

Ticker impact

$TMCIBullishMedium confidence
Context

CEO John T. Treace bought 55,944 shares for $246.7K, increasing his stake to over 7.4M shares.

Expected impact

Modest upside pressure in the next trading session.

Evidence & confidence

The purchase size is modest relative to float, but insider buying often influences market perception.

Market effects

Sector

None significant beyond the company.

Regional

No broader regional effect.

Global

Limited to TMCI investors.

Counterpoint

What could challenge this read

The purchase is too small to move the stock; market may ignore it.

Key entities

  • Person
    Treace John T.

    Chief Executive Officer of TMCI

  • Company
    Treace Medical Concepts, Inc.

    Medical device company listed on US exchange

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TMCI insider trading history →

Related articles

AUG 7
MedAI 8/10

Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary

Treace Medical Concepts reported Q2 2026 earnings call updates. Management cited higher case volumes and surgeon adoption of its bunion portfolio for sequential revenue growth, while YoY revenue fell due to lower kit sales to stocking distributors and mix shift to lower-priced minimally invasive products. Full-year 2026 revenue guidance was raised to $204M to $212M, with expectations for reduced cash usage and improved adjusted EBITDA leverage.

yahoo.com6 min
AUG 7
$TMCIMedAI 9/10

Treace Medical Concepts, Inc.: Treace Medical Concepts Reports Second Quarter 2026 Financial Results

Treace Medical Concepts (NasdaqGS: TMCI) reported Q2 2026 revenue of $45.4 million, down from $47.4 million in Q2 2025, with a net loss of $15.9 million and adjusted EBITDA loss of $3.5 million. Cash usage year to date fell 57% to $3.6 million, with $45.6 million cash and securities at June 30. The company raised 2026 revenue guidance to $204-$212 million and expects adjusted EBITDA loss of $3.0-$5.0 million.

finanznachrichten.de4 min
AUG 7
$TMCIMed

TREACE MEDICAL CONCEPTS, INC. (TMCI): Results of Operations and Financial Condition

TREACE MEDICAL CONCEPTS, INC. (TMCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla. – August 7, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment o

SEC EDGAR 8-K6 min
JUN 11
$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

rttnews.com7 min